Lupin Manufacturing Solutions hosted a panel discussion on CDMO consolidation with Eduardo Jule, PhD, Chief Commercial Officer, moderated by Bernardo Estupiñán Gaisbauer, CDMO Advisor LLC, and Lauren Schulte Kjeldsen, Evonik Industries AG.

Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of Lupin, specializes in delivering high-quality APIs and comprehensive CDMO services to accelerate drug development from bench to market. Backed by Lupin’s five decades of pharmaceutical expertise, LMS provides cost-effective, integrated solutions tailored to client needs. From R&D and process development to clinical manufacturing, large-scale production, and regulatory support, we offer end-to-end services that ensure seamless drug development and delivery. 𝐃𝐫𝐮𝐠 𝐒𝐮𝐛𝐬𝐭𝐚𝐧𝐜𝐞 Our strong legacy in API manufacturing and vertically integrated operations ensure uncompromising quality and cost efficiency. Since we are based in India, our manufacturing costs are significantly lower, enabling us to pass significant cost benefits to our clients. Sustainable practices are adopted throughout our value chain giving clients the advantage of reducing the impact of operations on the environment. 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐞𝐝 𝐎𝐟𝐟𝐞𝐫𝐢𝐧𝐠 Our R&D, Manufacturing, Quality, and Regulatory teams excel in diverse disciplines and have deep industry experience. This enables us to offer end-to-end product development, scale and commercialization, with a proven track record of securing regulatory approvals globally. Our world-class manufacturing facilities in Dabhasa and Vizag, a state-of-the-art R&D center in Pune, and a team with deep expertise position us as the partner of choice for API and CDMO solutions.